Supernus Pharmaceuticals (SUPN) Common Equity (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Common Equity of $1.0 billion for Q2 2026, down 3.07% year-over-year from $1.1 billion in Q2 2025, and down 4.23% on a QoQ basis from $1.1 billion in Q1 2026.
Supernus Pharmaceuticals (SUPN) Common Equity (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Common Equity for 16 years, with the latest figure at $1.0 billion in Q2 2026.
- Common Equity for Q2 2026 came in at $1.0 billion, down 3.07% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.0 billion (down 3.07% YoY), and the FY2025 annual result was $1.1 billion, up 2.51% from the prior year.
- Common Equity retreated to $1.0 billion in Q2 2026, from $1.1 billion in the prior quarter.
- Over five years, Common Equity peaked at $1.1 billion in Q1 2026 and troughed at $828.4 million in Q1 2022.
- A 5-year average of $962.1 million and a median of $943.3 million in 2024 frame the typical range for Common Equity.
- The widest annual swing landed in 2024, when Common Equity advanced 12.39%; it then fell 3.07% in 2026.
- A 5-year view of Common Equity shows it stood at $886.2 million in 2022, then grew by 3.98% to $921.5 million in 2023, then climbed by 12.39% to $1.0 billion in 2024, then grew by 2.51% to $1.1 billion in 2025, then dropped by 2.87% to $1.0 billion in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $1.0 billion in Q2 2026, $1.1 billion in Q1 2026, and $1.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 1.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 1.06 Bn |
| Sep 30, 2025 | 1.05 Bn |
| Jun 30, 2025 | 1.06 Bn |
| Mar 31, 2025 | 1.03 Bn |
| Dec 31, 2024 | 1.04 Bn |
| Sep 30, 2024 | 1.01 Bn |
| Jun 30, 2024 | 957.45 Mn |
| Mar 31, 2024 | 929.17 Mn |
| Dec 31, 2023 | 921.52 Mn |
| Sep 30, 2023 | 912.19 Mn |
| Jun 30, 2023 | 919.91 Mn |
| Mar 31, 2023 | 912.15 Mn |
| Dec 31, 2022 | 886.20 Mn |
| Sep 30, 2022 | 852.80 Mn |
| Jun 30, 2022 | 841.43 Mn |
| Mar 31, 2022 | 828.45 Mn |
| Dec 31, 2021 | 815.85 Mn |
| Sep 30, 2021 | 810.47 Mn |